HOME > TOP STORIES

TOP STORIES

REGULATORY MHLW Panel OKs List of “High-Priority” Vaccines, including Norovirus Jabs

March 14, 2025
REGULATORY Zepbound, Qalsody, and More New Drugs Set for Japan Listing on March 19

March 13, 2025
BUSINESS More than Half of Drug Makers’ Top 5 Meds See Flat or Positive Revisions: Poll

March 12, 2025
BUSINESS Two-Thirds of Drug Makers Discontent with FY2025 Price Revision: Survey

March 11, 2025
BUSINESS Drug Makers Weigh Withdrawal of Unprofitable Drugs, Generic and Innovative Players Alike: Poll

March 11, 2025
BUSINESS Japan Drug Makers See Varied Impact from 2025 Revision, Foreign Firms Take Hit: Poll

March 10, 2025
REGULATORY Stelara to Get 40.8% Price Cut on PMP Return, Januvia Over 26% in 2025 Revision

March 10, 2025
REGULATORY MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return

March 7, 2025
REGULATORY Takeda’s Livmarli, BMS’s Camzyos, and More Inch Closer to Japan Approval

March 7, 2025
ORGANIZATION Cough Drug Asverin Tops Supply Shortage Ranking in Japan: P-Cubed Survey

March 6, 2025
BUSINESS Unexpected Demand Triggers Supply Curb for Eisai’s ALS Med Just 3 Months after Launch; Patients Urge Early Response

March 5, 2025
BUSINESS Sumitomo Group Continues to Seek Best Partners for Pharma Biz

March 5, 2025
BUSINESS Japan Pharma Market Hits 11.5 Trillion Yen in 2024, Keytruda Wins Crown: IQVIA

March 5, 2025
COMMENTARY Evolving GLP-1 Drugs: Could Double and Triple Agonists Achieve Blockbuster Status?

March 4, 2025
BUSINESS 680 Employees Exit Takeda in Buyout Program, 10%-Plus of Japan Staff

March 4, 2025
REGULATORY No Prior Talks with US Drug Makers for Deferred PMP Price Cuts: Health Minister

March 3, 2025
REGULATORY J&J’s Lazcluze, Genmab’s Tivdak and More Drugs in Line for Japan Approval

February 28, 2025
ORGANIZATION JPMA President Demands Rethink of Social Security Expenditure Cap

February 27, 2025
ORGANIZATION Japan Pharma Lobbies Likely to Enter Yasukawa/Miyabashira Era toward FY2026 Reform

February 26, 2025
ACADEMIA 1st CP Inhibitor Approved for Sarcoma, Could This Be a Breakthrough to Treatment of More Subtypes?

February 25, 2025

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…